Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 8/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387927 | 1.00 | ALDH1A1 (0.48) | ALDH1A1GAAJAK2JAK1TYK2 | |
| SCHEMBL11893724 | 1.00 | ALDH1A1 (0.48) | ALDH1A1GAAJAK2JAK1TYK2 | |
| SCHEMBL11911197 | 1.00 | ALDH1A1 (0.48) | ALDH1A1GAAJAK2JAK1TYK2 | |
| SCHEMBL10332608 | 0.87 | CES2 (0.46) | ALDH1A1GAAJAK2JAK1TYK2 | |
| SCHEMBL20136432 | 0.87 | CES2 (0.46) | ALDH1A1GAAJAK2JAK1TYK2 | |
| SCHEMBL5775733 | 0.87 | CES2 (0.46) | ALDH1A1GAAJAK2JAK1TYK2 | |
| SCHEMBL2201612 | 0.85 | ALDH1A1 (0.58) | ALDH1A1JAK2JAK1TYK2KMT2A | |
| SCHEMBL10426802 | 0.85 | ALDH1A1 (0.58) | ALDH1A1JAK2JAK1TYK2KMT2A | |
| SCHEMBL1106341 | 0.85 | ALDH1A1 (0.58) | ALDH1A1JAK2JAK1TYK2KMT2A | |
| SCHEMBL23731404 | 0.78 | CES2 (0.39) | ALDH1A1GAAKMT2AMEN1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368145-A1 | METHODS FOR TREATING CANCER | IMMUNIC AG (DE) | 2024-11-07 | — | — | US | disclosed |
| EP-4074708-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | Immunic AG (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3679034-B1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | IMMUNIC AG (DE) | 2022-06-01 | — | — | EP | disclosed |
| US-11292788-B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IMMUNIC AG (DE) | 2022-04-05 | — | — | US | disclosed |
| US-20210061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IMMUNIC AG (DE) | 2021-03-04 | — | — | US | disclosed |
| CN-111433202-A | 1- (4- (isoxazol-5-yl) -1H-pyrazol-1-yl) -2-methylpropan-2-ol derivatives and related compounds as I L-17 and IFN-gamma inhibitors for the treatment of autoimmune diseases and chronic inflammation | 埃慕尼克股份公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3679034-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | Immunic AG (DE) | 2020-07-15 | — | — | EP | disclosed |
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-08-06 | — | — | US | disclosed |
| WO-2019048541-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | IMMUNIC AG (DE) | 2019-03-14 | — | — | WO | disclosed |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-8354436-B2 | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation | 4SC DISCOVERY GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196862-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| WO-2012101261-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMH (DE) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101263-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| EP-1224189-B1 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | BONJOUKLIAN ROSANNE (US) | 2004-04-22 | — | — | US | disclosed |
| US-6670373-B1 | Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide | ELI LILLY AND COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1224189-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027116-A2 | CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IFNG, IL17A, IFNAR1 | ALDH1A1 1850/4885GAA 3922/4885JAK2 34/4885 |
| US-20120196862-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | IFNG, IL17A, IL2 | ALDH1A1 1434/4885GAA 428/4885JAK2 93/4885 |
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 2556/4885GAA 1197/4885JAK2 3586/4885 |
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | IFNG, IL17A, IL2 | ALDH1A1 1434/4885GAA 428/4885JAK2 93/4885 |
| US-20240368145-A1 | METHODS FOR TREATING CANCER | CYP17A1, KLK3, ESRRB | ALDH1A1 104/4885GAA 3174/4885JAK2 2887/4885 |
| US-11292788-B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IFNG, IL17A, IFNAR1 | ALDH1A1 1850/4885GAA 3922/4885JAK2 34/4885 |
| US-20040077675-A1 | Compounds and methods for inhibiting MRP1 | ABCC1, ABCB1, ABCB11 | ALDH1A1 212/4885GAA 1120/4885JAK2 4423/4885 |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | ALDH1A1 2821/4885GAA 1420/4885JAK2 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.